Moxifloxacin: an assessment after 5 years of clinical useMOELLERING, Robert C.Clinical infectious diseases. 2005, Vol 41, issn 1058-4838, 77 p., SUP2Serial Issue

Antimicrobial safety : Focus on fluoroquinolonesOWENS, Robert C; AMBROSE, Paul G.Clinical infectious diseases. 2005, Vol 41, pp S144-S157, issn 1058-4838, SUP2Article

Mechanisms of resistance to quinolonesJACOBY, George A.Clinical infectious diseases. 2005, Vol 41, pp S120-S126, issn 1058-4838, SUP2Article

The quinolones : Past, present, and futureANDRIOLE, Vincent T.Clinical infectious diseases. 2005, Vol 41, pp S113-S119, issn 1058-4838, SUP2Article

Clinical implications of pharmacokinetics and pharmacodynamics of fluoroquinolonesWISPELWEY, Brian.Clinical infectious diseases. 2005, Vol 41, pp S127-S135, issn 1058-4838, SUP2Article

Current management of acute bacterial rhinosinusitis and the role of moxifloxacinANON, Jack B.Clinical infectious diseases. 2005, Vol 41, pp S167-S176, issn 1058-4838, SUP2Article

Challenges in the management of community-acquired pneumonia : The role of quinolones and moxifloxacinNIEDERMAN, Michael S.Clinical infectious diseases. 2005, Vol 41, pp S158-S166, issn 1058-4838, SUP2Article

Pharmacoeconomic considerations associated with the use of intravenous-to-oral moxifloxacin for community-acquired pneumoniaDAVIS, Susan L; DELGADO, George JR; MCKINNON, Peggy S et al.Clinical infectious diseases. 2005, Vol 41, pp S136-S143, issn 1058-4838, SUP2Article

Moxifloxacin for the treatment of acute exacerbations of chronic obstructive pulmonary diseaseSETHI, Sanjay.Clinical infectious diseases. 2005, Vol 41, pp S177-S185, issn 1058-4838, SUP2Article